MetaCap

Belite Bio (BLTE) vs Grifols S.A. (GRFS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Belite Bio (BLTE) has outperformed Grifols S.A. (GRFS) over the past year, gaining 5.7% versus a loss of 3.0%. Grifols S.A. is the larger company by market cap ($5.55 billion vs $5.17 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BLTE+5.66%GRFS-2.98%
+64%+22%-20%
Nov 21, 20251 yearNov 20, 2026
BLTE+1102.83%GRFS-24.04%
+1817%+842%-132%
Apr 25, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BLTE versus GRFS key metrics
MetricBLTEGRFS
Share price$127.38$8.15
Market cap$5.17B$5.55B
1-day change-15.65%-0.61%
YTD return-20.37%-12.83%
1-year return+5.66%-2.98%
5-year return—-25.30%
P/E ratio (TTM)—9.82
Forward P/E—6.55
EPS (TTM)$-2.84$0.83
Dividend yield0.00%1.30%
Annual dividend$0.00$0.00
Net income (latest FY)$-77.61M—
52-week high$200.00$9.77
52-week low$115.41$6.96
Distance from 52-week high-36.31%-16.58%
Analyst consensusstrong_buybuy
Avg. price target upside+82.92%+27.24%
Average volume195.65K628.64K
Shares outstanding40.61M258.22M
Employees4125,000
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Grifols S.A. offers a meaningfully higher dividend yield (1.30% vs 0.00%).

About Belite Bio

BLTE stock →

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees

About Grifols S.A.

GRFS stock →

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.

Health Care · Biotechnology: Pharmaceutical Preparations · 25,000 employees

BLTE vs GRFS FAQ

Which is bigger, Belite Bio or Grifols S.A.?

Grifols S.A. (GRFS) is larger, with a market capitalization of $5.55B compared with $5.17B for Belite Bio (BLTE).

Which stock has performed better over the past year, BLTE or GRFS?

BLTE returned +5.66% over the past 12 months, compared with -2.98% for GRFS (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Belite Bio or Grifols S.A.?

Grifols S.A. pays a dividend yielding 1.30%, while Belite Bio does not currently pay a regular dividend.

Are Belite Bio and Grifols S.A. in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons